Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2617)	9/29/2009 11:26:33 AM
From: Jibacoa	Respond to of 3722

NLTX is still up 28.79% on low volume. It announced today the appointment of Arie S. Belldegrun, M.D., FACS to its board of directors. In July it raised $3.4M in a private placement of stock and warrants. The stock needs to close above the $2 level before it can resume the UT that started on May 15 at the $0.50 level and was stopped on Aug 26 at the $2.30 level.<g> bigcharts.marketwatch.com NETX has NLTD, the insiders hold >30%, It is expected to trim its losses in 2009 & 2010 to $0.30 & $0.20 from the $0.54 loss in 2008 The ACTAY is $4.50. My 'target' is lower, on a close above $2 and with some good news, I think that the stock could get to test the $3 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2617)	10/5/2009 12:03:19 PM
From: Jibacoa	Respond to of 3722

CYCCP is up 27.08% on very low volume.(Only 100 shrs traded <g>) It is till below the resistance at $2 There are no news, that I am aware, since the CEO presented at R&R Annual Healthcare conference in NY on Sep10 CYCCP is planning to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products. Its Sapacitabine,is a cell cycle modulating nucleoside analog, that is in PII for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in PI in combination with seliciclib. Seliciclib, is a CDK inhibitor, which is in PII for the treatment of lung and nasopharyngeal cancer. It also has CYC116, an Aurora kinase and VEGFR2 inhibitor, which is in PI for patients with solid tumors. Its subsidiary, ALIGN Pharmaceuticals, markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn Liquid and Numoisyn Lozenges for xerostomia. On Aug 28 it said that it had received a letter the NASDAQ Listing Qualifications Department notifying that it does not comply with the $10M minimum stockholders' equity required for continued listing on NAZ's Global Market (At that time the Company's stockholders' equity was reported at around $8.2M) That was based on data as of June 30 and the price has improved some since then.<g> It seems that the stock needs to get back above $3 in order to be compliant with the NAZ requirements.<g> bigcharts.marketwatch.com Bernard